Unknown

Dataset Information

0

Utilization of Rad51C promoter for transcriptional targeting of cancer cells.


ABSTRACT: Cancer therapy that specifically targets malignant cells with minimal or no toxicity to normal tissue has been a long-standing goal of cancer research. Rad51 expression is elevated in a wide range of cancers and Rad51 promoter has been used to transcriptionally target tumor cells, however, a large size of Rad51 promoter limits its application for gene therapy. To identify novel tumor-specific promoters, we examined expression levels of Rad51 paralogs, Rad51B, Rad51C, and Rad51D as well as Rad52 in a panel of normal and tumor cell lines. We found that Rad51C is significantly overexpressed in cancer cells. The expression was up-regulated by approximately 6-fold at the mRNA level and 9-fold at the protein level. Interestingly, the 2064 bp long Rad51C promoter fragment was approximately 300-fold higher in cancer cells than in normal cells. A construct containing Rad51C promoter driving diphtheria toxin A efficiently killed several types of cancer cells with very mild effect to normal cells. These results underscore the potential of targeting the homologous recombination pathway in cancer cells and provide a proof of principle that the Rad51C promoter fragment can be used to transcriptionally target cancer cells.

SUBMITTER: Cao Y 

PROVIDER: S-EPMC4039114 | biostudies-other | 2014 Apr

REPOSITORIES: biostudies-other

altmetric image

Publications

Utilization of Rad51C promoter for transcriptional targeting of cancer cells.

Cao Yan Y   Xu Yan Y   Zhang Lei L   Li Zhen Z   Jiang Ying Y   Tian Xiao X   Seluanov Andrei A   Gorbunova Vera V   Mao Zhiyong Z  

Oncotarget 20140401 7


Cancer therapy that specifically targets malignant cells with minimal or no toxicity to normal tissue has been a long-standing goal of cancer research. Rad51 expression is elevated in a wide range of cancers and Rad51 promoter has been used to transcriptionally target tumor cells, however, a large size of Rad51 promoter limits its application for gene therapy. To identify novel tumor-specific promoters, we examined expression levels of Rad51 paralogs, Rad51B, Rad51C, and Rad51D as well as Rad52  ...[more]

Similar Datasets

| S-EPMC10706967 | biostudies-literature
| S-EPMC3018173 | biostudies-literature
| S-EPMC3471399 | biostudies-literature
| S-EPMC6953820 | biostudies-literature
| S-EPMC2629396 | biostudies-literature
| S-EPMC3666257 | biostudies-literature
| S-EPMC3894581 | biostudies-literature
| S-EPMC4398258 | biostudies-literature
| S-EPMC4942663 | biostudies-literature
| S-EPMC2911447 | biostudies-literature